

# CITATION REPORT

List of articles citing

**Pertuzumab for the Neoadjuvant Treatment of Early-Stage HER2-Positive Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appr**

**DOI: 10.1007/s40273-017-0556-7**  
**Pharmacoeconomics, 2018, 36, 29-38.**

**Source:** <https://exaly.com/paper-pdf/69776073/citation-report.pdf>

**Version:** 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
12	Expression of M2 macrophage markers YKL-39 and CCL18 in breast cancer is associated with the effect of neoadjuvant chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2018</b> , 82, 99-109	3.5	23
11	Combination therapies for the treatment of HER2-positive breast cancer: current and future prospects. <i>Expert Review of Anticancer Therapy</i> , <b>2018</b> , 18, 629-649	3.5	20
10	Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States. <i>Value in Health</i> , <b>2019</b> , 22, 408-415	3.3	18
9	Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement. <i>Oncologist</i> , <b>2019</b> , 24, 603-611	5.7	20
8	Pertuzumab in the treatment of HER2-positive breast cancer: an evidence-based review of its safety, efficacy, and place in therapy. <i>Core Evidence</i> , <b>2019</b> , 14, 51-70	4.9	23
7	The Efficacy of Pegylated Liposomal Doxorubicin-Based Neoadjuvant Chemotherapy in Breast Cancer: A Retrospective Case-Control Study in Taiwan. <i>Biochemistry Research International</i> , <b>2020</b> , 2020, 5729389	2.4	1
6	A 10-Gene Signature for Predicting the Response to Neoadjuvant Trastuzumab Therapy in HER2-Positive Breast Cancer. <i>Clinical Breast Cancer</i> , <b>2021</b> , 21, e654-e664	3	3
5	Precision treatment exploration of breast cancer based on heterogeneity analysis of lncRNAs at the single-cell level. <i>BMC Cancer</i> , <b>2021</b> , 21, 918	4.8	0
4	The addition of neoadjuvant pertuzumab for the treatment of HER2+ breast cancer: a cost estimate with real-world data. <i>Health Economics Review</i> , <b>2021</b> , 11, 33	2	0
3	A Canadian national guideline on the neoadjuvant treatment of invasive breast cancer, including patient assessment, systemic therapy, and local management principles.. <i>Breast Cancer Research and Treatment</i> , <b>2022</b> , 193, 1	4.4	1
2	Dual neoadjuvant blockade plus chemotherapy versus monotherapy for the treatment of women with non-metastatic HER2-positive breast cancer: a systematic review and meta-analysis.		0
1	Pertuzumab in Combination with Trastuzumab and Docetaxel in the Neoadjuvant Treatment for HER2-Positive Breast Cancer. <b>2022</b> ,		0